FDA Adverse Event Injury Summary report: N

FINELINE II

MDR report key: 3043334 · Received April 9, 2013

Report

Report Number
2124215-2013-02176
Event Type
Injury
Date Received
April 9, 2013
Date of Event
December 12, 2012
Report Date
February 5, 2013
Manufacturer
CPI - DEL CARIBE
Product Code
NVN
Adverse Event
Yes
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
AR
Reporter Occupation
MEDICAL EQUIPMENT COMPANY TECHNICIAN/REPRESENTATIVE

Narratives

Additional Manufacturer Narrative · 1

THE PRODUCT HAS BEEN RECEIVED FOR ANALYSIS. THIS REPORT WILL BE UPDATED UPON COMPLETION OF ANALYSIS.

Additional Manufacturer Narrative · 1

UPON RECEIPT AT OUR POST MARKET QUALITY ASSURANCE LABORATORY, A THOROUGH EVALUATION OF THE LEAD WAS PERFORMED. RESISTANCE TESTS WERE COMPLETED TO ASSESS LEAD ELECTRICAL PERFORMANCE. MEASUREMENTS THROUGHOUT THESE TESTS WERE WITHIN NORMAL LIMITS. MICROSCOPIC INSPECTIONS OF THE TERMINAL PIN ASSEMBLY, LEAD BODY, AND ELECTRODE TIP FOUND NO ANOMALIES. LABORATORY TESTING WAS UNABLE TO REPRODUCE THE REPORTED CLINICAL OBSERVATIONS AND DETAILED ANALYSIS DID NOT REVEAL ANY ABNORMALITIES.

Description of Event or Problem · 1

BOSTON SCIENTIFIC RECEIVED INFORMATION THAT THIS RIGHT ATRIAL (RA) LEAD EXHIBITED INTERMITTENT LOSS OF CAPTURE AT MAXIMUM OUTPUTS, AN INCREASE IN PACING IMPEDANCES, UNDERSENSING, AS WELL AS SOME OVERSENSING. SURGICAL INTERVENTION WAS PERFORMED AND UNDER FLUOROSCOPIC EVALUATION THE LEAD WAS OBSERVED TO BE DISLODGED AND HANGING LOOSELY IN THE SUPERIOR VENA CAVA. THE LEAD WAS SUCCESSFULLY EXPLANTED AND A NEW RA LEAD WAS IMPLANTED. NO ADDITIONAL ADVERSE PATIENT EFFECTS WERE REPORTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
146264 FINELINE II IMPLANTABLE LEAD NVN CPI - DEL CARIBE 4469

Patients

Seq Age Sex Outcome Treatment
1 77 YR Hospitalization| L| R 4469| 4136| K173